---
category: news
title: "Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC"
excerpt: "OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (\"Galmed\" or the \"Company\"), a"
publishedDateTime: 2023-07-10T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
webUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
ampWebUrl: "https://www.benzinga.com/amp/content/33164058"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/33164058"
type: article

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "w/ahTt2ltT1Is/kgEtTEephg1dtXf5czWjK5yRLw/OUqT/Bxrg4ljdPDamEMjUddF/owiqpW4u1LvA0G8PAXU9STJCV277Z/za5I2RTVdI/nN4EoyInYvOAD5vAaHOd5IJA9qMOf2niXwkSoeQIqFVSKatz9xVKZr94wnaCh+coMXfLeTu5BHO8awNqWLnQ/60+QC1XCNU4Ebu78mIowYso5mlEdvM/R07h7ZqIO9EHOKSypqE/t0eRwDd8D3P8D4QIzZddv89nvLx8dKzNpwt8mtqAWEsWkv4LDIhPI5R09yTvtEpNedwRvmPlqQyX+YK9YPm5wAlRA2DCUef3EwRbId41GlhYmdRx6tfTgizY=;5UQIcLUnaMCjnxs0dS4Kyg=="
---

